▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

tmfebcapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Feb 5, 2014 by Todd Campbell

Gilead Sciences, Inc Has a Potential Blockbuster Drug for 2014

Gilead's (GILD) may hit blockbuster $1 billion a year status in its first year on the market.

Feb 5, 2014 by Todd Campbell

Here's Why Palbociclib is Helping Pfizer Avoid the Sell-Off

Positive news on Pfizer's (PFE) promising breast cancer treatment is helping prop up the company's shares

Feb 5, 2014 by Todd Campbell

Here's Why Big Pharma is Rooting for Portola

Pfizer (PFE), Bristol-Myers (BMY), Johnson & Johnson (JNJ) and Bayer (BAYRY) stand to make big money if Portola's anti-coagulant antidote succeeds.

Feb 4, 2014 by Todd Campbell

Novartis AG: Combating $2 Billion in Lost Sales

Novartis (NVS) is taking heavy hits from the patent cliff, but Gilenya and Afinitor are two high growth bright spots.

Feb 3, 2014 by Todd Campbell

Xgeva and Prolia: Setting the Pace for Amgen, Inc.

Amgen's bone-bulking drugs Xgeva and Prolia are winning market share from Novartis' (NVS) Zometa.

Feb 3, 2014 by Todd Campbell

Teva: Attempting to Dodge Wrenches

The threat to $4 billion in sales for Teva's (TEVA) blockbuster Copaxone has the company making moves to protect its MS market share.

Feb 2, 2014 by Todd Campbell

What Does Dendreon Corporation's Fourth Quarter Mean For Investors?

Sales of Dendreon's (DNDN) prostate drug Provenge bounced back in the fourth quarter, but the recovery may not warrant buying shares -- yet.

Feb 2, 2014 by Todd Campbell

Forest Laboratories, Inc.: Feelings of Deja Vu?

Forest's upcoming patent expiration for its best selling drug smacks of when Lexapro went off patent in 2012.

Jan 29, 2014 by Todd Campbell

4 Insurers Benefiting From Medicaid Reform

The Affordable Care Act is resulting in millions of new Medicaid members worth billions in payments to these companies.

Jan 29, 2014 by Todd Campbell

3 Companies Working on Parkinson's Treatments You Ought to Know About

Parkinson's may be tough-to-treat, but Chelsea (CHTP), Avanir (AVNR), and Prothena (PRTA) are hard at work developing new treatments.

Jan 29, 2014 by Todd Campbell

Medivation Inc. and Astellas Up the Ante against Johnson & Johnson

Positive late stage results pave the way for Medivation and Astellas to expand Xtandi's label, putting it even more directly in competition with Johnson's Zytiga.

Jan 29, 2014 by Todd Campbell

Will New Generics Push Mylan Inc.'s Shares Higher?

Generic drug launches will pick back up in 2014 and 2015, boosting sales for drugmaker Mylan.

Jan 28, 2014 by Todd Campbell

Digesting Pfizer's Fourth Quarter Results

Generic competition is taking a toll on Pfizer, but it may not be as bad as it looks

Jan 27, 2014 by Todd Campbell

Sales of Pfizer Inc. and Bristol-Myers Squibb Co.'s Eliquis Thicken

Pfizer (PFE) and Bristol's (BMY) blood thinning drug Eliquis may be gaining ground on Johnson & Johnson (JNJ) and Boehringer.

Jan 27, 2014 by Todd Campbell

Sanofi's OK in the U.K. Poses a Threat to Novartis

Oral MS treatments from Sanofi (SNY), Novartis (NVS), and Biogen (BIIB) will jockey for position overseas this year.

Jan 26, 2014 by Todd Campbell

Here's How Forest Laboratories, Inc. is Surviving in the Post Lexapro World

Forest (FRX) hopes its new depression drugs will recapture market share lost when its $2 billion a year Lexapro went off-patent in 2012.

Jan 24, 2014 by Todd Campbell

GlaxoSmithKline's Eperzan Gets Closer to Launch

Glaxo's (GSK) Eperzan is about to face-off against GLP-1 drugs from Novo (NVO), AstraZeneca (AZN), and Lilly LLY).

Jan 23, 2014 by Todd Campbell

Here's What You Need to Know about Amgen, Inc's AMG-145

Positive data out of Amgen (AMGN) for AMG-145 may bode well for future growth.

Jan 23, 2014 by Todd Campbell

Merck's RNAi Trash is Alnylam's Treasure

Alnylam acquired Merck's RNAi patent portfolio for a fraction of Merck's cost. Is this a good deal for both parties?

Jan 22, 2014 by Todd Campbell

Slowing Sales for Johnson & Johnson's Zytiga May Be Good News for Medivation

Sales momentum for Johnson & Johnson's (JNJ) Zytiga is slowing in the United States as competitor Medivation (MDVN) jockeys for position.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services